Martinello M; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ, 2019, 'Cure and Control: What Will It Take to Eliminate HCV?', in Topics in Medicinal Chemistry, pp. 447 - 490, http://dx.doi.org/10.1007/7355_2018_56
Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P, 2020, 'Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs.', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciaa253
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M, 2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, http://dx.doi.org/10.1016/j.jhep.2019.11.012
Grebely J; Catlett B; Jayasinghe I; Valerio H; Hajarizadeh B; Verich A; Cunningham P; Martinello M; Tillakeratne S; Silk D, 2020, 'Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a more rapid time to diagnosis.', J Infect Dis, http://dx.doi.org/10.1093/infdis/jiaa037
He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ, 2020, 'Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma', Alimentary Pharmacology and Therapeutics, vol. 51, pp. 34 - 52, http://dx.doi.org/10.1111/apt.15598
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M, 2019, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife s', Journal of Viral Hepatitis, http://dx.doi.org/10.1111/jvh.13233
Moradi G; Hajarizadeh B; Rahmani K; Mohamadi-Bolbanabad A; Darvishi S; Zareie B; Zavareh FA; Sharafi H; Alavian SM; Ramazani R, 2019, 'Drug use and risk behaviour profile, and the prevalence of HIV, hepatitis C and hepatitis B among people with methamphetamine use in Iran', International Journal of Drug Policy, vol. 73, pp. 129 - 134, http://dx.doi.org/10.1016/j.drugpo.2019.09.018
Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J, 2019, 'Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciz1089
Catlett B; Lamoury FMJ; Bajis S; Hajarizadeh B; Martinez D; Mowat Y; Cunningham PH; Jacka BP; Cloherty GA; Marks P, 2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, vol. 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196
Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C, 2019, 'Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all', International Journal of Drug Policy, vol. 72, pp. 1 - 10, http://dx.doi.org/10.1016/j.drugpo.2019.07.016
Alavi M; Poustchi H; Merat S; Kaveh-ei S; Rahimi-Movaghar A; Shadloo B; Hajarizadeh B; Grebely J; Dore GJ; Malekzadeh R, 2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, vol. 72, pp. 99 - 105, http://dx.doi.org/10.1016/j.drugpo.2019.07.002
Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P, 2019, 'Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with di', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciz633
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ, 2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, vol. 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P, 2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness', Journal of Viral Hepatitis, vol. 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, 2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, vol. 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013
Wallace J; Smith E; Hajarizadeh B; Richmond J; Lucke J, 2019, 'Addressing cultural diversity: the hepatitis B clinical specialist perspective', Ethnicity and Health, vol. 24, pp. 816 - 828, http://dx.doi.org/10.1080/13557858.2017.1370540
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Cover Image', Journal of Viral Hepatitis, vol. 25, pp. i - i, http://dx.doi.org/10.1111/jvh.12604
Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J, 2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2
Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, vol. 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013
Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V, 2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, vol. 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, vol. 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004
Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, vol. 20, pp. 621 - 627, http://dx.doi.org/10.1016/j.jmoldx.2018.05.010
Major M; Gutfraind A; Shekhtman L; Cui Q; Kachko A; Cotler SJ; Hajarizadeh B; Sacks-Davis R; Page K; Boodram B, 2018, 'Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users', Science Translational Medicine, vol. 10, http://dx.doi.org/10.1126/scitranslmed.aao4496
Dore GJ; Hajarizadeh B, 2018, 'Elimination of Hepatitis C Virus in Australia: Laying the Foundation', Infectious Disease Clinics of North America, vol. 32, pp. 269 - 279, http://dx.doi.org/10.1016/j.idc.2018.02.006
Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, vol. 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2018, 'Management of acute HCV infection in the era of direct-acting antiviral therapy', Nature Reviews Gastroenterology and Hepatology, vol. 15, pp. 412 - 424, http://dx.doi.org/10.1038/s41575-018-0026-5
Alavi M; Grebely J; Hajarizadeh B; Amin J; Larney S; Law MG; George J; Degenhardt L; Dore GJ, 2018, 'Mortality trends among people with hepatitis B and C: A population-based linkage study, 1993-2012', BMC Infectious Diseases, vol. 18, http://dx.doi.org/10.1186/s12879-018-3110-0
Razavi-Shearer D; Gamkrelidze I; Nguyen MH; Chen DS; Van Damme P; Abbas Z; Abdulla M; Abou Rached A; Adda D; Aho I, 2018, 'Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 383 - 403, http://dx.doi.org/10.1016/S2468-1253(18)30056-6
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio H; Hajarizadeh B; Hayes PC; Krajden M, 2018, 'Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study', Journal of Viral Hepatitis, vol. 25, pp. 473 - 481, http://dx.doi.org/10.1111/jvh.12837
Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1
Martinello M; Hajarizadeh B; Dore GJ, 2018, 'Observations on the launch of new drugs for hepatitis C', Australian Prescriber, vol. 41, pp. 4 - 5, http://dx.doi.org/10.18773/austprescr.2018.005
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2018, 'Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia', Journal of Viral Hepatitis, vol. 25, pp. 640 - 648, http://dx.doi.org/10.1111/jvh.12852
Cunningham EB; Hajarizadeh B; Amin J; Bretana N; Dore GJ; Degenhardt L; Larney S; Luciani F; Lloyd AR; Grebely J, 2018, 'Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study', International Journal of Drug Policy, vol. 54, pp. 18 - 25, http://dx.doi.org/10.1016/j.drugpo.2017.12.013
Esmaeili A; Mirzazadeh A; Morris MD; Hajarizadeh B; Sacks HS; Maher L; Grebely J; Kim AY; Lauer G; Cox AL, 2018, 'The Effect of Female Sex on Hepatitis C Incidence among People Who Inject Drugs: Results from the International Multicohort InC3 Collaborative', Clinical Infectious Diseases, vol. 66, pp. 20 - 28, http://dx.doi.org/10.1093/cid/cix768
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M, 2018, 'The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study', Journal of Hepatology, vol. 68, pp. 393 - 401, http://dx.doi.org/10.1016/j.jhep.2017.10.019
Shepherd SJ; McDonald SA; Palmateer NE; Gunson RN; Aitken C; Dore GJ; Goldberg DJ; Applegate TL; Lloyd AR; Hajarizadeh B, 2018, 'HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype', Journal of Medical Virology, vol. 90, pp. 120 - 130, http://dx.doi.org/10.1002/jmv.24919
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2017, 'Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014).', Hepatol Commun, vol. 1, pp. 736 - 747, http://dx.doi.org/10.1002/hep4.1073
Grebely J; Hajarizadeh B; Dore GJ, 2017, 'Direct-Acting antiviral agents for HCV infection affecting people who inject drugs', Nature Reviews Gastroenterology and Hepatology, vol. 14, pp. 641 - 651, http://dx.doi.org/10.1038/nrgastro.2017.106
Hajarizadeh B; Mesgarpour B; Nasiri MJ; Alavian SM; Merat S; Poustchi H; Malekzadeh R; Sedaghat A; Haghdoost AA, 2017, 'Estimating the prevalence of hepatitis B virus infection and exposure among general population in Iran', Hepatitis Monthly, vol. 17, http://dx.doi.org/10.5812/hepatmon.11715
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression', Journal of Hepatology, vol. 67, pp. 1204 - 1212, http://dx.doi.org/10.1016/j.jhep.2017.07.025
Wallace J; Pitts M; Liu C; Lin V; Hajarizadeh B; Richmond J; Locarnini S, 2017, 'More than a virus: A qualitative study of the social implications of hepatitis B infection in China', International Journal for Equity in Health, vol. 16, http://dx.doi.org/10.1186/s12939-017-0637-4
Bajis S; Dore GJ; Hajarizadeh B; Cunningham EB; Maher L; Grebely J, 2017, 'Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review', International Journal of Drug Policy, vol. 47, pp. 34 - 46, http://dx.doi.org/10.1016/j.drugpo.2017.07.002
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020
Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-017-2517-3
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV, 2017, 'HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs', Current HIV/AIDS Reports, vol. 14, pp. 110 - 121, http://dx.doi.org/10.1007/s11904-017-0358-8
Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, vol. 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007
Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR, 2017, 'Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study', Journal of Viral Hepatitis, vol. 24, pp. 733 - 741, http://dx.doi.org/10.1111/jvh.12701
Blach S; Zeuzem S; Manns M; Altraif I; Duberg AS; Muljono DH; Waked I; Alavian SM; Lee MH; Negro F, 2017, 'Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 161 - 176, http://dx.doi.org/10.1016/S2468-1253(16)30181-9
Hajarizadeh B; Grebely J; McManus H; Estes C; Razavi H; Gray RT; Alavi M; Amin J; McGregor S; Sievert W, 2017, 'Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment', Journal of Gastroenterology and Hepatology (Australia), vol. 32, pp. 229 - 236, http://dx.doi.org/10.1111/jgh.13453
Esmaeili A; Mirzazadeh A; Carter GM; Esmaeili A; Hajarizadeh B; Sacks HS; Page KA, 2017, 'Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis', Journal of Viral Hepatitis, vol. 24, pp. 117 - 127, http://dx.doi.org/10.1111/jvh.12628
Hajarizadeh B; Grebely J; Martinello M; Matthews GV; Lloyd AR; Dore GJ, 2016, 'Hepatitis C treatment as prevention: evidence, feasibility, and challenges', The Lancet Gastroenterology and Hepatology, vol. 1, pp. 317 - 327, http://dx.doi.org/10.1016/S2468-1253(16)30075-9
Alavi M; Law MG; Grebely J; Amin J; Hajarizadeh B; George J; Dore GJ, 2016, 'Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study', Journal of Hepatology, vol. 65, pp. 879 - 887, http://dx.doi.org/10.1016/j.jhep.2016.06.025
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews GV; Law M; Dore GJ, 2016, 'Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)', Journal of Hepatology, vol. 65, pp. 1086 - 1093, http://dx.doi.org/10.1016/j.jhep.2016.08.010
Alavian SM; Hajarizadeh B; Lankarani KB; Sharafi H; Daryani NE; Merat S; Mohraz M; Mardani M; Fattahi MR; Poustchi H, 2016, 'Recommendations for the clinical management of hepatitis C in Iran: A consensus-based national guideline', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.guideline
Hajarizadeh B; Richmond J; Ngo N; Lucke J; Wallace J, 2016, 'Hepatitis B-related concerns and anxieties among people with chronic hepatitis B in Australia', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.35566
Hajarizadeh B; Razavi-Shearer D; Merat S; Alavian SM; Malekzadeh R; Razavi H, 2016, 'Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden', Hepatitis Monthly, vol. 16, http://dx.doi.org/10.5812/hepatmon.37234
Sheridan DA; Hajarizadeh B; Fenwick FI; Matthews GV; Applegate T; Douglas M; Neely D; Askew B; Dore GJ; Lloyd AR, 2016, 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection', Liver International, vol. 36, pp. 1774 - 1782, http://dx.doi.org/10.1111/liv.13176
Hajarizadeh B; Lamoury FMJ; Feld JJ; Amin J; Keoshkerian E; Matthews GV; Hellard M; Dore GJ; Lloyd AR; Grebely J, 2016, 'Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection', Virology Journal, vol. 13, http://dx.doi.org/10.1186/s12985-016-0482-x
Lamoury FMJ; Hajarizadeh B; Keoshkerian E; Feld JJ; Amin J; Teutsch S; Matthews GV; Hellard M; Dore GJ; Lloyd AR, 2016, 'HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection', BMC Infectious Diseases, vol. 16, http://dx.doi.org/10.1186/s12879-016-1567-2
Bartlett SR; Jacka B; Bull RA; Luciani F; Matthews GV; Lamoury FMJ; Hellard ME; Hajarizadeh B; Teutsch S; White B, 2016, 'HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection', Infection, Genetics and Evolution, vol. 37, pp. 252 - 258, http://dx.doi.org/10.1016/j.meegid.2015.11.028
Richmond J; Hajarizadeh B; Wallace J, 2015, 'Patients' perspectives on the delivery of hepatitis B management and care', Australian family physician, vol. 44, pp. 346
Hajarizadeh B; Wallace J; Richmond J; Ngo N; Enright C, 2015, 'Hepatitis B knowledge and associated factors among people with chronic hepatitis B', Australian and New Zealand Journal of Public Health, vol. 39, pp. 563 - 568, http://dx.doi.org/10.1111/1753-6405.12378
Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, vol. 17, pp. 583 - 589, http://dx.doi.org/10.1016/j.jmoldx.2015.05.003
Sibley A; Han KH; Abourached A; Lesmana LA; Makara M; Jafri W; Salupere R; Assiri AM; Goldis A; Abaalkhail F, 2015, 'The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 21 - 41, http://dx.doi.org/10.1111/jvh.12476
Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC3 study', Journal of Infectious Diseases, vol. 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220
Alfaleh FZ; Nugrahini N; Matičič M; Tolmane I; Alzaabi M; Hajarizadeh B; Valantinas J; Kim DY; Hunyady B; Abaalkhail F, 2015, 'Strategies to manage hepatitis C virus infection disease burden - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 42 - 65, http://dx.doi.org/10.1111/jvh.12474
Liakina V; Hamid S; Tanaka J; Olafsson S; Sharara AI; Alavian SM; Gheorghe L; El Hassan ES; Abaalkhail F; Abbas Z, 2015, 'Historical epidemiology of hepatitis C virus (HCV) in select countries - Volume 3', Journal of Viral Hepatitis, vol. 22, pp. 4 - 20, http://dx.doi.org/10.1111/jvh.12475
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study', Journal of Viral Hepatitis, vol. 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384
Hajarizadeh B; Wallace J; Richmond J; Ngo N; Enright C, 2015, 'Hepatitis B knowledge and associated factors among people with chronic hepatitis B', Australian and New Zealand Journal of Public Health, http://dx.doi.org/10.1111/1753-6405.12378
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC3 study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0122232
Hajarizadeh B; Grebely J; Applegate T; Matthews GV; Amin J; Petoumenos K; Hellard M; Rawlinson W; Lloyd A; Kaldor J, 2014, 'Dynamics of HCV RNA Levels During Acute Hepatitis C Virus Infection', Journal of Medical Virology, vol. 86, pp. 1722 - 1729, http://dx.doi.org/10.1002/jmv.24010
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, vol. 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027
Keshvari M; Sharafi H; Hajarizadeh B; Alavian SM, 2014, 'Can we include genetic variants with high linkage disequilibrium into a multiple logistic model?', Liver International, vol. 34, pp. 964 - 964, http://dx.doi.org/10.1111/liv.12464
Grebely J; Page K; Sacks-Davis R; van der Loeff MS; Rice TM; Bruneau J; Morris MD; Hajarizadeh B; Amin J; Cox AL, 2014, 'The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection', Hepatology, vol. 59, pp. 109 - 120, http://dx.doi.org/10.1002/hep.26639
Grebely J; Hajarizadeh B; Dore GJ; Grady B; Page K, 2014, 'Disease progression during advanced fibrosis: IL28B genotype or HCV RNA levels?', Hepatology, http://dx.doi.org/10.1002/hep.26675
Keshvari M; Pouryasin A; Behnava B; Sharafi H; Hajarizadeh B; Alavian SM, 2014, 'Letter: The rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C', Alimentary Pharmacology and Therapeutics, vol. 39, pp. 343, http://dx.doi.org/10.1111/apt.12589
Mirzazadeh A; Salimzadeh H; Arabi M; Hajarizadeh B; Navadeh S; Haghdoost AA, 2013, 'Trends of obesity in Iranian adults from 1990s to late 2000s; a Systematic Review and Meta-analysis', Middle East Journal of Digestive Diseases, vol. 5, pp. 151 - 157, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990178/
Wallace J; Hajarizadeh B; Richmond J; McNally S, 2013, 'Challenges in managing patients in Australia with chronic hepatitis B: The General Practitioners' perspective', Australian and New Zealand Journal of Public Health, vol. 37, pp. 405 - 410, http://dx.doi.org/10.1111/1753-6405.12127
Hajarizadeh B; Grebely J; Dore GJ, 2013, 'Epidemiology and natural history of HCV infection', Nature Reviews Gastroenterology and Hepatology, vol. 10, pp. 553 - 562, http://dx.doi.org/10.1038/nrgastro.2013.107
Wallace J; McNally S; Richmond J; Hajarizadeh B; Pitts M, 2012, 'Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia', Sexual Health, vol. 9, pp. 131 - 137, http://dx.doi.org/10.1071/SH10137
Wallace J; Hajarizadeh B; Richmond J; McNally S; Pitts M, 2012, 'Managing chronic hepatitis B The role of the GP', Australian Family Physician, vol. 41, pp. 893 - 898
Hajarizadeh B; Grebely J; Dore GJ, 2012, 'Case definitions for acute hepatitis C virus infection: A systematic review', Journal of Hepatology, vol. 57, pp. 1349 - 1360, http://dx.doi.org/10.1016/j.jhep.2012.07.007
Wallace J; McNally S; Richmond J; Hajarizadeh B; Pitts M, 2011, 'Managing chronic hepatitis B: A qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia', BMC Research Notes, vol. 4, http://dx.doi.org/10.1186/1756-0500-4-45
Alavian SM; Mohammad-Alizadeh AH; Esna-Ashari F; Ardalan G; Hajarizadeh B, 2009, 'Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures', Liver International, vol. 29, pp. 159 - 163, http://dx.doi.org/10.1111/j.1478-3231.2008.01790.x
Tavallaii SA; Mirzamani M; Heshmatzade Behzadi A; Assari S; Khoddami Vishteh HR; Hajarizadeh B; Einollahi B, 2009, 'Sexual function: A comparison between male renal transplant recipients and hemodialysis patients', Journal of Sexual Medicine, vol. 6, pp. 142 - 148, http://dx.doi.org/10.1111/j.1743-6109.2008.01047.x
Movahedi M; Hajarizadeh B; Rahimi A; Arshinchi M; Amirhosseini K; Haghdoost AA, 2009, 'Trends and geographical inequalities of the main health indicators for rural Iran', Health Policy and Planning, vol. 24, pp. 229 - 237, http://dx.doi.org/10.1093/heapol/czp007
Alavian SM; Gooya MM; Hajarizadeh B; Esteghamati AR; Moeinzadeh AM; Haghazali M; Zamani GA; Yaghini F; Lankarani KB, 2009, 'Mass vaccination campaign against hepatitis B in adolescents in Iran: Estimating coverage using administrative data', Hepatitis Monthly, vol. 9, pp. 189 - 195
Shariat-Torbaghan S; Emami-Aleagha M; Sedighi S; Azadbakht F; Keshvari A; Hajarizadeh B; Rosai J, 2009, 'Squamous cell carcinoma arising in an ovarian mature cystic teratoma: A case report', Archives of Iranian Medicine, vol. 12, pp. 186 - 189
Sali S; Alavian SM; Hajarizadeh B, 2008, 'Effect of levamisole supplementation on hepatitis B virus vaccination response in hemodialysis patients', Nephrology, vol. 13, pp. 376 - 379, http://dx.doi.org/10.1111/j.1440-1797.2008.00952.x
Movahedi M; Haghdoost AA; Pournik O; Hajarizadeh B; Fallah MS, 2008, 'Temporal variations of health indicators in Iran comparing with other Eastern Mediterranean Region countries in the last two decades', Journal of Public Health, vol. 30, pp. 499 - 504, http://dx.doi.org/10.1093/pubmed/fdn071
Alavian SM; Hajarizadeh B; Ahmadzad-Asl M; Kabir A; Bagheri-Lankarani K, 2008, 'Hepatitis B virus infection in Iran: A systematic review', Hepatitis Monthly, vol. 8, pp. 281 - 294
Haghdoost AA; Sadeghirad B; Hajarizadeh B; Mirzazadeh A, 2007, 'The application of Systematic Review and Meta-analysis concepts in summarizing the findings of observational studies', Iranian Journal of Psychiatry, vol. 2, pp. 132 - 136, http://ijps.tums.ac.ir/index.php/ijps/article/view/453
Mirmomen S; Alavian SM; Hajarizadeh B; Kafaee J; Yektaparast B; Zahedi MJ; Zand V; Azami AA; Hosseini MMA; Faridi AR, 2006, 'Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassemia in Iran: A multicenter study', Archives of Iranian Medicine, vol. 9, pp. 319 - 323
Jahani MR; Alavian SM; Shirzad H; Kabir A; Hajarizadeh B, 2005, 'Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with "illegal social behaviour" [9]', Sexually Transmitted Infections, vol. 81, pp. 185, http://dx.doi.org/10.1136/sti.2004.011114
Alavian SM; Hajarizadeh B; Hajibeigi B; Doroudi T; Hamedianizadeh AK; Abar K, 2004, 'Efficacy and Safety of Pegylated Interferon Alfa-2a plus Ribavirin for Treatment of Chronic Hepatitis C and Cirrhosis in Iranians', Hepatitis Monthly, vol. 4, pp. 53 - 58, http://hepatmon.portal.tools/?page=article&article_id=668
Alavian SM; Hajarizadeh B, 2004, 'Attempted suicide in two patients with chronic hepatitis C while being treated with Interferon-alpha', Hepatitis Monthly, vol. 4, pp. 20 - 22, http://hepatmon.portal.tools/?page=article&article_id=691
Alavian SM; Kabir A; Hajarizadeh B; Nayebpour M; Haji Beigi B; Doroudi T; Baralle F, 2004, 'Combination Therapy of Interferon-alpha (PDferon B®) and Ribavirin for Chronic Hepatitis C', Hepatitis Monthly, vol. 4, pp. 13 - 16, http://hepatmon.portal.tools/?page=article&article_id=689
Alavian SM; Hajarizadeh B, 2004, 'Remarkable difference in the mode of HCV transmission among haemodialysis patients and IVDAs [7]', Gut, vol. 53, pp. 1057
Alavian SM; Hajarizadeh B; Nematizadeh F; Larijini B, 2004, 'Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease', BMC Endocrine Disorders, vol. 4, http://dx.doi.org/10.1186/1472-6823-4-4
Einollahi B; Hajarizadeh B; Bakhtiari S; Lesanpezeshki M; Khatami MR; Nourbala MH; Pourfarziani V; Alavian SM, 2003, 'Pretransplant hepatitis C virus infection and its effect on the post-transplant course of living renal allograft recipients', Journal of Gastroenterology and Hepatology (Australia), vol. 18, pp. 836 - 840, http://dx.doi.org/10.1046/j.1440-1746.2003.03063.x
Alavian SM; Einollahi B; Hajarizadeh B; Bakhtiari S; Nafar M; Ahrabi S, 2003, 'Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients', Nephrology, vol. 8, pp. 256 - 260, http://dx.doi.org/10.1046/j.1440-1797.2003.00166.x
Einollahi B; Hajarizadeh B; Simforoosh N; Lessanpezeshki M; Khatami MR; Nourbala MH; Basiri A; Pourfarziani V; Firoozan A; Nafar M, 2003, 'Patient and graft outcome after living donor renal transplantation in Iran: More than 15-year follow-up', Transplantation Proceedings, vol. 35, pp. 2605 - 2606, http://dx.doi.org/10.1016/j.transproceed.2003.09.075
Simforoosh N; Basiri A; Pourrezagholi F; Einolahi B; Firouzan A; Moghaddam MM; Nourbala MH; Hajarizadeh B; Pourfarziani V; Lessanpezeshki M, 2003, 'Is preemptive renal transplantation preferred?', Transplantation Proceedings, vol. 35, pp. 2598 - 2601, http://dx.doi.org/10.1016/j.transproceed.2003.09.026
Alavian SM; Hajarizadeh B; Einollahi B, 2003, 'Efficacy and safety of lamivudine for treatment of chronic hepatitis B in renal allograft recipients', Transplantation Proceedings, vol. 35, pp. 2687 - 2688, http://dx.doi.org/10.1016/j.transproceed.2003.08.042
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin N; Mchutchison JG; Brainard D, 2018, 'Incidence of hepatitis C virus infection in four prisons in New South Wales, Australia: The SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Paris, FRANCE, pp. S187 - S188, presented at International Liver Congress (ILC), Paris, FRANCE, 11 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30587-7
Lamoury F; Bajis S; Hajarizadeh B; Marshall A; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J, 2018, 'Evaluation of the Xpert fingerstick HCV viral load assay', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Paris, FRANCE, pp. S167 - S167, presented at International Liver Congress (ILC), Paris, FRANCE, 11 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30546-4
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; Mchutchison JG; Brainard DM, 2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, pp. S274 - S274, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30862-0
Cunningham EB; Hajarizadeh B; Amin J; Bretana NA; Luciani F; Degenhardt L; Larney S; Dore GJ; Lloyd AR; Grebely J, 2017, 'Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, pp. S488 - S488, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31370-3
Cunningham EB; Luciani F; Hajarizadeh B; Betz-Stablein B; Bretana NA; Teutsch S; Dore GJ; Grebely J; Lloyd AR, 2016, 'STABLE INCIDENCE OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WITH A HISTORY OF INJECTING DRUG USE IN AN AUSTRALIAN PRISON SETTING, 2005-2014: THE HITS-P STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, pp. S614 - S614, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01138-7
Hajarizadeh B; Grebely J; Byrne M; Marks P; Butler T; Amin J; Vickerman P; Martin NK; McHutchison JG; Brainard DM, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, Boston, MA, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Grady B; Page K; Kim AY; Mcgovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M, 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: The InC3 study', in Journal of Viral Hepatitis, Blackwell Publishing Ltd, http://dx.doi.org/10.1111/jvh.12384
Sheridan DA; Hajarizadeh B; Matthews G; Applegate TL; Douglas MW; Askew B; Neely D; Bassendine MF; Dore GJ; Lloyd AR, 2014, 'Hepatitis C lipoviral particle levels are associated with spontaneous clearance of acute infection', in HEPATOLOGY, WILEY-BLACKWELL, Boston, MA, pp. 929A - 929A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 07 - 11 November 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804082&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Grady BP; Page K; Kim AY; McGovern BH; Cox A; Rice TM; Sacks-Davis R; Bruneau J; Morris MD, 2014, 'Patterns of hepatitis C virus RNA levels during acute infection: the InC3 study', in HEPATOLOGY, WILEY-BLACKWELL, Boston, MA, pp. 898A - 899A, presented at 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 07 - 11 November 2014, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344483804020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kwon JA; Dore G; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2018, 'Australia on track to achieve WHO elimination targets following rapid initial DAA treatment uptake', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Paris, FRANCE, Vol. 68, pp. S153 - S153, presented at International Liver Congress (ILC), Paris, FRANCE, 11 - 15 April 2018, http://dx.doi.org/10.1016/S0168-8278(18)30518-X
Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Homie R; Gray RT, 2018, 'Ongoing Burden of Advanced Liver Disease Complications Despite Rapid HCV Treatment Scale-Up', Australasian Viral Hepatitis Conference, presented at Australasian Viral Hepatitis Conference, 13 - 15 August 2018
Kwon A; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'Australia Could Meet the WHO HCV Elimination Targets If the Current Rollout of DAA Treatment Is Continued', Australasian Viral Hepatitis Conference (AVHC), presented at Australasian Viral Hepatitis Conference (AVHC), 10 - 11 August 2017
Byrne M; Hajarizadeh B; Dore GJ; Treloar C; Marks P; Milat A; Bowman J; McGrath C; Bath N; Calder I, 2017, 'A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S495 - S495, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31387-9
Hajarizadeh B; Grebely J; Matthews GV; Martinello M; Dore GJ, 2017, 'The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S291 - S292, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30899-1
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ, 2017, 'No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S12 - S12, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30286-6
Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G, 2016, 'HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, Vol. 64, pp. S625 - S626, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01163-6
Hajarizadeh B; Grebely J; Matthews G; Martinello M; Dore G, 2016, 'Treatment uptake for chronic hepatitis C in Australia following universal access to interferon-free treatments', in HEPATOLOGY, WILEY, Boston, MA, Vol. 64, pp. 948A - 948A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804277&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Waziry R; Grebely J; Amin J; Alavi M; Hajarizadeh B; George J; Matthews G; Law M; Dore G, 2016, 'Survival following hepatocellular carcinoma among people with HBV or HCV in New South Wales, Australia between 2000 and 2014', in HEPATOLOGY, WILEY, Boston, MA, Vol. 64, pp. 886A - 886A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493804156&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J, 2015, 'EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, Vol. 62, pp. S657 - S657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 22 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31050-3
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Reid H; Janjua N; Midgard H; Dalgard O; Dillon J, 2019, 'HEPATITIS C VIRUS REINFECTION FOLLOWING ANTIVIRAL TREATMENT AMONG PEOPLE WHO USE OR INJECT DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S50 - S51, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100127&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Marshall AD; Grebely J; Dore GJ; Treloar C; Corry A; Hayllar J; Byrne J, 2019, 'SYMPOSIUM: ENHANCING HEPATITIS C CARE AMONG PEOPLE WHO INJECT DRUGS', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 38, pp. S8 - S9, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000494890100017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
He S; Dore G; Law M; Heahter V; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'IMPROVED SURVIVAL FOLLOWING HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA DIAGNOSIS IN THE DIRECT-ACTING ANTIVIRAL THERAPY ERA IN NEW SOUTH WALES, AUSTRALIA', in HEPATOLOGY, WILEY, Boston, MA, Vol. 70, pp. 906A - 906A, presented at Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Boston, MA, 08 - 12 November 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000488653503195&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
He S; Hajarizadeh B; Lockart I; Alavi M; Danta M; Dore G, 2019, 'Effectiveness of direct-acting antiviral therapy for hepatitis C among people with hepatocellular carcinoma: A systematic review and meta-analysis', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 71 - 72, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
He S; Dore G; Law M; Valerio H; Grebely J; Amin J; Hajarizadeh B; George J; Danta M; Alavi M, 2019, 'Improved survival after hepatitis C-related hepatocellular carcinoma diagnosis in the direct-acting antiviral therapy era in New South Wales, Australia', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 34, pp. 82 - 82, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000483843100132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Reid H; Law M; Janjua N; Midgard H; Dalgard O; Dillon J, 2019, 'Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vienna, AUSTRIA, Vol. 70, pp. E733 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, AUSTRIA, 10 - 14 April 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703223&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Cunningham EB; Dalgard O; Hajarizadeh B; Conway B; Powis J; Bruneau J; Feld J; Read P; Cooper C, 2019, 'Reinfection following successful HCV DAA therapy among people with recent injecting drug use', in JOURNAL OF HEPATOLOGY, ELSEVIER, Vienna, AUSTRIA, Vol. 70, pp. E732 - E733, presented at International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, AUSTRIA, 10 - 14 April 2019, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000463481703222&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Dalgard O; Grebely J; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL, 2018, 'Sofosbuvir and Velpatasvir for Hepatitis C Virus Infection in People with Recent Injecting Drug Use (Simplify): An Open-Label, Single-Arm, Phase 4, Multicentre Trial', in HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, PACINI EDITORE, Vol. 20, pp. 14 - 14, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000440974900004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Yee J; Dore GJ; Hanson J; Iser D; Danta M; Shaw D; Read P; Balcomb A; Post J; Faros J, 2018, 'High efficacy of HCV therapy following universal DAA access in Australia: the REACH-C cohort', in JOURNAL OF VIRAL HEPATITIS, WILEY, Toronto, CANADA, Vol. 25, pp. 54 - 54, presented at 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD), Toronto, CANADA, 14 - 17 June 2018, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000435101000087&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL, 2017, 'EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR IN PEOPLE WITH CHRONIC HEPATITIS C VIRUS INFECTION AND RECENT INJECTING DRUG USE: THE SIMPLIFY STUDY', in DRUG AND ALCOHOL REVIEW, WILEY, Vol. 36, pp. 34 - 34, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000424000500085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 - 23 April 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, UNSW Sydney
Hajarizadeh B, 2017, Generic direct acting antiviral treatment: The first step towards elimination of hepatitis C in Iran, http://dx.doi.org/10.5812/hepatmon.45788
